Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma

Background/ObjectiveWhile several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. Axillary lymph node metastasis (ALNM) is one of the most important prognostic determinants in breast carcinoma; however, the reasons why tumors vary in their capability to result in axillary metastasis remain unclear. Identifying breast carcinoma patients at risk for ALNM would improve treatment planning. This study aimed to identify the factors associated with ALNM in breast carcinoma, with particular emphasis on basal-like phenotype.MethodsBreast carcinoma patients (n = 210) who underwent breast conserving surgery and axillary lymph node dissection (ALND) (level I and II) or modified radical mastectomy were included in this study. Pathological and immunohistochemical data including individual receptor/gene status was collected for analysis. The basal phenotype status was ascertained using the basal cytokeratin markers CK5, CK14, CK17 and EGFR.ResultsALNM was found in 55% (n = 116) of the patients. On univariate analysis, multicentric disease, large tumor size (>2 cm), vascular and lymphatic invasion, epithelial hyperplasia, necrosis, in situ carcinoma and perineural invasion were associated with higher risk for ALNM, whereas CK5, CK14, EGFR positivity and basal-like tumor type were associated with lower risk. On multivariate analysis, CK5 positivity (OR 0.003, 95%CI 0.000-0.23, p = 0.009) and lymphatic/vascular invasion (OR 17.94, 95%CI 4.78-67.30, p < 0.001) were found to be independent predictors.ConclusionsAlthough the value of complete ALND has been questioned in invasive breast cancer patients, treatment decisions for breast carcinoma have been influenced by many parameters, including lymph node status. Since histopathologic characteristics and expression of biological markers varies among the same histologic subtypes of breast carcinoma, specific clinical and histopathologic features of the primary tumor and ALN status like sentinel node might be used to tailor the loco-regional and systemic treatment in different clinical settings.

[1]  Hiroko Yamashita,et al.  Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer , 2003, Breast Cancer Research.

[2]  R. Schmidt,et al.  Patient selection for breast conservation therapy with magnification mammography. , 1995, Surgery.

[3]  Gregory Y. Lauwers,et al.  Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast , 2009 .

[4]  L. Sobin,et al.  Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma , 2003, Cancer.

[5]  W. Yang,et al.  Impact of patient age on the outcome of primary breast carcinoma * , 2002, Journal of surgical oncology.

[6]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[7]  G. Pruneri,et al.  Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution , 2005, Cancer.

[8]  Jorge S. Reis-Filho,et al.  Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.

[9]  S. Paik,et al.  Pathologic findings from the national surgical adjuvant breast project (protocol 6) I. Intraductal carcinoma (DCIS) , 1986, Cancer.

[10]  A. Chott,et al.  Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. , 1989, Oncology.

[11]  L. Norton,et al.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[13]  A. Luini,et al.  Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[15]  A. Bednarek,et al.  Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer , 2006, Oncology.

[16]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  L. Bégin,et al.  The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.

[18]  M. Seoud,et al.  Effects of young age at presentation on survival in breast cancer , 2006, BMC Cancer.

[19]  T. Petit,et al.  Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.

[20]  Donald L Weaver,et al.  Protocol for the examination of specimens from patients with invasive carcinoma of the breast. , 2009, Archives of pathology & laboratory medicine.

[21]  C. Mettlin,et al.  Global breast cancer mortality statistics , 1999, CA: a cancer journal for clinicians.

[22]  G. Murphy,et al.  Management and survival of female breast cancer: Results of a national survey by the American college of surgeons , 1980, Cancer.

[23]  D. Barnes,et al.  The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. , 1983, British Journal of Cancer.

[24]  D. Schultz,et al.  The influence of young age on outcome in early stage breast cancer. , 1994, International journal of radiation oncology, biology, physics.

[25]  Douglas Macmillan,et al.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.

[26]  R. Simmons,et al.  Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. , 2000, Journal of the American College of Surgeons.

[27]  D. Herceg,et al.  Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients , 2010, Medical oncology.

[28]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Chott,et al.  K-67 Immunoreactivity in Breast Carcinomas in Relation to Transferrin Receptor Expression, Estrogen Receptor Status and Morphological Criteria , 1989 .

[30]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Sapino,et al.  Meta‐analysis of non‐sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer , 2004, The British journal of surgery.

[32]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[33]  John Boyages,et al.  Multifocal and multicentric breast cancer: does each focus matter? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Ernst,et al.  Early and late morbidity associated with axillary levels I–III dissection in breast cancer , 2002, Journal of surgical oncology.

[36]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[37]  T. Shibata,et al.  Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy , 2010, Modern Pathology.

[38]  I. Ellis,et al.  Chapter 19 – Histologic Grade , 2006 .

[39]  T. Shibata,et al.  Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. , 2010, Human pathology.

[40]  R. Moll,et al.  Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.

[41]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[42]  M. Silverstein,et al.  Predicting Axillary Nodal Positivity in 2282 Patients with Breast Carcinoma , 2001, World Journal of Surgery.

[43]  C. Redmond,et al.  Pathologic findings from the national surgical adjuvant breast project (protocol 4): Discriminants for 15‐year survival , 1993, Cancer.

[44]  J. Robertson,et al.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.

[45]  R. Nagle,et al.  Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[46]  H. Weiss,et al.  Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre‐ and postmenopausal women , 2002, International journal of cancer.

[47]  H. Bingham.  Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4) , 1985 .

[48]  Y. Suh,et al.  Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.

[49]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[50]  R. Severson,et al.  Axillary lymph node metastases associated with small invasive breast carcinomas , 1999, Cancer.

[51]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[52]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[53]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[54]  S. Schnitt,et al.  Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[55]  A. Hackett,et al.  MONOCLONAL MARKER THAT PREDICTS EARLY RECURRENCE OF BREAST CANCER , 1987, The Lancet.

[56]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  H. Kang,et al.  Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. , 2011, Oncology reports.

[58]  L. Goldstein,et al.  Prognostic and predictive factors in early-stage breast cancer. , 2004, The oncologist.

[59]  A. Luini,et al.  Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. Hanlon,et al.  Identification of women with T1‐T2 breast cancer at low risk of positive axillary nodes , 1997, Journal of surgical oncology.

[61]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[62]  Jiong Wu,et al.  Basal Cytokeratin Expression in Relation to Immunohistochemical and Clinical Characterization in Breast Cancer Patients with Triple Negative Phenotype , 2009, Tumori.

[63]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[64]  P. Guldberg,et al.  Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients , 2000, Breast Cancer Research.

[65]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[66]  U. Chetty,et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.